Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01373502
Other study ID # C20902
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2009
Est. completion date October 2015

Study information

Verified date April 2018
Source CID - Carbostent & Implantable Devices
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate non-inferiority in terms of safety and efficacy of DES Limus Carbostent compared to the Taxus Liberté in treating de-novo atherosclerotic lesions in native coronary arteries.


Recruitment information / eligibility

Status Completed
Enrollment 323
Est. completion date October 2015
Est. primary completion date April 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years

- Patient is eligible for percutaneous coronary intervention (PCI) and for surgical revascularization (CABG)

- Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee of the respective clinical site

- Patients with clinical evidence of ischemic heart disease and/or a positive functional study(e.g. stress test); documented stable (CCS I-IV) or unstable angina pectoris (Braunwald class I-II B and C) or documented silent ischemia

- LVEF>30%

- Requires treatment of a single de novo lesion in a native coronary artery in one or two different major epicardial vessels (LAD, LCX or RCA). The second lesion must fit with inclusion/exclusion criteria and must be treated with the same study stent as the first lesion

- Target lesion should be located in a target vessel with a diameter ranging from 3.0 to 3.75 mm

- Target lesion diameter stenosis > 50% and < 100% by visual estimate, with a TIMI flow of = 1

- The target lesion must be appropriately covered (margin of 2.5 mm on both sides of the stent) by one study stent (DES Limus Carbostent or Taxus Liberté, according to the randomization arm). Any occurred dissection of the target vessel must be treated with an additional stent (DES Limus Carbostent or Taxus Liberté, according to the randomization arm)

- Patient that underwent BMS implantation more than 6 months before the enrolment or DES implantation more than 1 year before the enrolment in an other vessel.

Exclusion Criteria:

- Female with childbearing potential or lactating

- Known sensitivity to sirolimus, paclitaxel, the polymeric matrix, stainless steel or cobalt chromium

- Acute Q-wave or non Q-wave myocardial infarction within 72 hours, or presents with CK elevation greater than 2 times upper limit normal associated with elevated CK-MB

- Cardiogenic shock

- Cerebrovascular accident within the past 6 months

- Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl)

- Contraindication to aspirin or clopidogrel

- Thrombocytopenia (platelet count less than 100,000/mm³)

- Active gastrointestinal bleeding within the past 3 months

- Known bleeding or hypercoagulable disorder

- Prior anaphylactic reaction to contrast agents or contrast sensitivity that cannot be controlled with pre-medication

- Currently under immunosuppressant therapy

- Currently, or has been treated with either Rapamune or paclitaxel within 12 months of the procedure

- Active infection

- Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;

- Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study

- Patient underwent coronary revascularization to any vessel within 30 days

- Patient underwent target vessel revascularization within 6 months

- Target vessel has had prior stent placement

- Presence of two lesions located in the same vascular territory (same major epicardial vessel)

- Prior coronary brachytherapy

- There is a planned target lesion treatment with any technique other than the pre-dilatation balloon angioplasty

- Treatment of more than two lesions is required at the time of enrolment, or is planned within 30 days following enrolment

- Any planned surgery within 6 months after index procedure

- Left main disease greater than 50% diameter stenosis

- Significant (>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off

- Heavily calcified vessel and/or lesion which cannot be successfully predilated

- Target lesion is located or supplied by an arterial or venous bypass graft

- Ostial target lesion or lesion located within 2 mm of a bifurcation

- Target lesion involves a side branch >2.0 mm in diameter with an ostial disease

- Target lesion has TIMI 0 flow

- Target vessel with angiographically visible thrombus or unsuitable for proper stent delivery and deployment.

Study Design


Intervention

Device:
DES Limus Carbostent
DES Limus Carbostent Carbofilm Coated Coronary Stent
Taxus Liberté Stent
Taxus Liberté Coronary Stent

Locations

Country Name City State
Belgium Academisch Ziekenhuis Middelheim Antwerpen
Belgium Ziekenhuis Oost Limburg Genk
France Clinique les Franciscaines Nimes
France Institut Mutualiste Montsouris Paris
France Clinique Saint-Hilaire Rouen
France Hôpital de Rangueil Toulouse Cedex 4
Germany Medizinisches Versorgungszentrum Hamburg
Germany Krankenhaus der Barmherzigen Brüder Trier
Italy Azienda Ospedaliera Careggi Firenze
Italy Istituto di Fisiologia Clinica del CNR Massa
Italy Ospedale S. Camillo Roma

Sponsors (1)

Lead Sponsor Collaborator
CID - Carbostent & Implantable Devices

Countries where clinical trial is conducted

Belgium,  France,  Germany,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary angiographic efficacy measurement (mm) in-stent Late Lumen Loss (LLL) measurement by angiography 180 days
Secondary QCA measurements in-stent and in-segment 180 days
Secondary IVUS measurements 180 days
Secondary Incidence of cardiac death (%) 30 days, 180 days, 1, 2 , 3, 4 and 5 years
Secondary Stent Thrombosis acute, 30 days, 180 days, 1 year, > 1 year
Secondary Acute success (Device and Procedural success) acute
Secondary Incidence of Myocardial Infarction (%) 30 days, 180 days, 1, 2, 3, 4, 5 years
Secondary Incidence of clinically indicated TLR (%) 30 days, 180 days, 1, 2, 3, 4, 5 years
Secondary Incidence of all deaths (%) 30 days, 180 days, 1, 2, 3, 4, 5 years
Secondary Incidence of all repeat revascularization (%) 30 days, 180 days, 1, 2, 3, 4, 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Not yet recruiting NCT02550301 - Does Mean Platelet Volume Change With Clopidogrel N/A
Completed NCT02252406 - Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Phase 4
Active, not recruiting NCT02244853 - Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease N/A
Not yet recruiting NCT01162902 - Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Phase 4
Completed NCT01826552 - Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent Phase 4
Completed NCT02126150 - United Coronary Biobanks N/A
Completed NCT01769079 - Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina Phase 4
Completed NCT01328470 - Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease Phase 4
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00263263 - RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent. Phase 2
Active, not recruiting NCT04929496 - Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Recruiting NCT05459051 - Finding the Invasive Haemodynamic Threshold for Symptom Relief in Stable Angina
Completed NCT06464276 - Effectiveness and Tolerability of Trimetazidine 80mg Once Daily in Patients With Chronic Coronary Syndrome: The V-GOOD Study
Not yet recruiting NCT04403048 - Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID N/A
Completed NCT01974492 - Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting N/A
Completed NCT01990924 - Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention N/A
Completed NCT02120859 - Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Phase 4

External Links